|
|
|
|
To evaluate the efficacy and safety of metrifonate,an acetylcholinesterase inhibitor,in patients clinically diagnosed with probable Alzheimer's disease(AD)of mild to moderate severity.Metrifonate adverse events were predominantly mild in intensity.No hepatotoxicity was observed.Metrifonate was safe and well-tolerated.It enhanced not only the cognitive and global function,but also the behavioral function of patients diagnosed with mild to moderate AD.Therefore,metrifonate appears to be useful in the symptomatic treatment of AD. |
|